Risk for dementia found to be similar with SGLT2 inhibitors, dulaglutide in type 2 diabetes

For older adults with kind 2 diabetes, the danger for dementia appears related with sodium-glucose cotransporter 2 (SGLT2) inhibitors and the glucagon-like peptide 1 receptor agonist (GLP-1 RA) dulaglutide, in accordance with a examine printed on-line Aug. 27 within the Annals of Internal Medicine.

Bin Hong, from the School of Pharmacy at Sungkyunkwan University in Suwon, South Korea, and colleagues in contrast the danger for dementia between SGLT2 inhibitors and dulaglutide in a goal trial emulation examine utilizing nationwide well being care knowledge for South Korea obtained between 2010 and 2022.

Participants had been aged 60 years or older with kind 2 diabetes and had been initiating remedy with SGLT2 inhibitors (12,489 sufferers; 51.9 p.c dapagliflozin and 48.1 p.c empagliflozin) or dulaglutide (1,075 sufferers).

The researchers discovered that in a median follow-up of 4.4 years, the first consequence occasion of presumed medical onset of dementia occurred in 69 and 43 members within the SGLT2 and dulaglutide teams, respectively, with an estimated threat distinction of −0.91 share factors (95 p.c confidence interval, −2.45 to 0.63) and estimated threat ratio of 0.81 (95 p.c confidence interval, 0.56 to 1.16).

“In conclusion, we discovered little distinction within the threat for dementia for SGLT2 inhibitors in contrast with dulaglutide in our knowledge,” the authors write. “However, whether or not these findings generalize to newer GLP-1 RAs is unsure.”

Copyright © 2024 HealthDay. All rights reserved.